Posts tagged as

COMPPARE

A Patient’s Perspective: Dan McCarthy’s Journey to New Beginnings

Seven years ago, a routine physical for Dan McCarthy yielded an unexpected and unwelcome result: an elevated PSA and a recommendation for a biopsy. Dan and his wife Cindy O’Connell (shown right) couldn’t have been more shocked when the results were positive for prostate cancer. “There is no family history…

COMPPARE Consortium Spotlight: The ProCure Proton Therapy Center

ProCure Proton Therapy Center opened its doors in Somerset NJ in March 2012, becoming the tri-state region’s first and longest-established proton therapy facility. Eight years later, in October 2020, the center marked another milestone: a prostate cancer patient became the 5,000th person treated with proton therapy at…

COMPPARE Newsletter: Summer 2023

A Message from Dr. Nancy Mendenhall Since COMPPARE was launched in 2017, new information has emerged that suggests there may be other differences in outcomes between photon and proton radiation in prostate cancer. We would like to answer as many of these questions as…

What’s Next for COMPPARE?

Patient accrual has closed. Now, it’s up to participants to continue to complete COMPPARE’s Quality of Life and Side Effects Follow-up Questionnaires.

Once Again, A Lapse in Screening Can be Costly

By Bob Marckini Last month, a gentleman told us, sadly, that his father had died from prostate cancer. He then admitted he’d met with his primary care doctor only sporadically over the years and, despite this, didn’t even have regular PSA tests or DREs. Further, he skipped doctors’ visits completely…

What’s Next for COMPPARE?

Patient Accrual Closes, Participant Surveys are Collected, and Data Analysis Begins In 2017, a research team led by Nancy Mendenhall, M.D., medical director of the UF Health Proton Therapy Institute, was awarded a five-year, $11.9 million grant from the Patient-Centered Outcomes Research Institute (PCORI) to directly compare…

COMPPARE Consortium Spotlight: The MUSC Hollings Cancer Center

Dr. Nancy Mendenhall discusses COMPPARE with the MUSC radiation oncology team. The Medical University of South Carolina, Charleston (MUSC), founded in 1824, is South Carolina’s sole integrated academic health sciences center. Similarly, MUSC’s Hollings Cancer Center, one of 71 National Cancer Institute-designated cancer centers in the nation,…

COMPPARE Newsletter: Fall/Winter 2022-23

A Message from Dr. Nancy Mendenhall I am excited to share with you that on October 31, 2022, COMPPARE closed enrollment with a total of 2,524 participants (1,024 photon patients and 1,500 proton patients; 900 pragmatic, 600 randomized)! Read Dr. Mendenhall’s message.   Partner Site…

COMPPARE Enrolls 1,000th Photon Patient

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal. COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC, which…

COMPPARE Newsletter: Spring/Summer 2022

A Message from Dr. Nancy Mendenhall As we near the completion of COMPPARE’s overall enrollment objective – a total of 3,000 patients – we are beginning to reflect and evaluate what we’ve learned thus far in creating and carrying out a large, multi-institutional pragmatic…